Atezolizumab plus nab-paclitaxel for unresectable, locally advanced or metastatic breast cancer: Real-world results from a single academic center in Austria

IMpassion130 led to the approval of atezolizumab plus nab-paclitaxel as first-line treatment for patients with unresectable locally advanced or metastatic triple-negative, PD-L1 immune-cell positive breast cancer (BC) by the European Medicines Agency (EMA). The objective of the present study was to investigate the implementation, safety and efcacy of this combination in the initial phase after approval.